Reaction

Chronic Graft Versus Host Disease In Skin reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 899 reports · 39 co-occurring drugs

As of the last recalculation, Chronic Graft Versus Host Disease In Skin appears in 899 FAERS reports alongside 39 co-occurring drug terms. The strongest observed disproportionality signal is THIOTEPA (PRR 260.4).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Thiotepa	96	260.4	263.1
Fludarabine Phosphate	280	239.0	240.7
Busulfan	134	231.5	233.5
Sirolimus	69	128.4	129.0
Mycophenolate Mofetil	372	107.5	107.8
Mycophenolate Mofetil Hydrochloride	372	107.3	107.6
Melphalan	91	102.9	103.4
Tacrolimus Ointment 0.1%	339	100.6	100.8
Tacrolimus Extended-Release Capsules	339	100.3	100.6
Melphalan Hydrochloride	91	93.4	93.7
Alemtuzumab	70	90.8	91.1
Imatinib	62	87.3	87.7
Tacrolimus	352	84.9	85.1
Cyclosporine	249	71.3	71.4
Blinatumomab	18	40.7	40.8
Ganciclovir	17	39.2	39.2
Ganciclovir Sodium	17	37.9	37.9
Cyclophosphamide Injection, Solution	213	36.2	36.2
Cyclophosphamide	213	36.2	36.2
Cyclophosphamide For Injection	213	36.2	36.2
Ruxolitinib	91	32.6	32.6
Anti-Thymocyte Globulin (Rabbit)	11	31.9	32.0
Mycophenilic Acid	23	26.3	26.4
Posaconazole Delayed-Release	12	25.6	25.7
Voriconazole Injection	23	25.1	25.2
Micafungin Sodium	9	24.8	24.8
Posaconazole	16	23.2	23.2
Atovaquone	7	20.3	20.3
Mesna Injection	7	19.8	19.8
Voriconazole	25	19.6	19.6
Mesna	7	19.4	19.4
Mycophenolic Acid	25	18.6	18.6
Cytarabine	45	18.2	18.2
Basiliximab	9	17.9	17.9
Hydroxyurea	13	14.4	14.4
Clobetasol Propionate Ointment Usp, 0.05%	6	13.6	13.6
Clobetasol Propionate	6	13.5	13.5
Azacitidine For	10	12.9	12.9
Azacitidine	14	11.1	11.1

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.